163 related articles for article (PubMed ID: 38413420)
21. Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma.
Bi Y; Wang Y; Zhang W; Lu H; Ren J; Han X
Cancer Imaging; 2023 Feb; 23(1):19. PubMed ID: 36814327
[TBL] [Abstract][Full Text] [Related]
22. Comparison of CalliSpheres
Shi Z; Wang D; Kang T; Yi R; Cui L; Jiang H
Radiol Oncol; 2023 Mar; 57(1):70-79. PubMed ID: 36794998
[TBL] [Abstract][Full Text] [Related]
23. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up.
Ou HY; Wu YN; Yu CY; Chen CL; Hsu HW; Weng CC; Leung-Chit Tsang L; Huang TL; Tong YS; Lim WX; Cheng YF
J Vasc Interv Radiol; 2020 Nov; 31(11):1784-1791. PubMed ID: 33023805
[TBL] [Abstract][Full Text] [Related]
24. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
25. Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study.
Richter G; Radeleff B; Stroszczynski C; Pereira P; Helmberger T; Barakat M; Huppert P
Cardiovasc Intervent Radiol; 2018 Apr; 41(4):587-593. PubMed ID: 29167967
[TBL] [Abstract][Full Text] [Related]
26. Drug-Eluting Microsphere Versus Cisplatin-Based Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: Propensity Score-Matched Analysis.
Chu HH; Gwon DI; Kim JH; Ko GY; Shin JH; Yoon HK
AJR Am J Roentgenol; 2020 Sep; 215(3):745-752. PubMed ID: 32569514
[No Abstract] [Full Text] [Related]
27. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
Seki A; Hori S
Cardiovasc Intervent Radiol; 2012 Jun; 35(3):555-62. PubMed ID: 21562932
[TBL] [Abstract][Full Text] [Related]
28. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
[TBL] [Abstract][Full Text] [Related]
29. [Clinical investigation on transarterial chemoembolization with indigenous drug-eluting beads in treatment of unresectable hepatocellular carcinoma].
Chen G; Zhang D; Ying Y; Wang Z; Tao W; Zhu H; Zhang J; Peng Z
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):44-51. PubMed ID: 28436630
[TBL] [Abstract][Full Text] [Related]
30. Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma: does size really matter?
Lee SY; Ou HY; Yu CY; Huang TL; Tsang LL; Cheng YF
Diagn Interv Radiol; 2020 May; 26(3):230-235. PubMed ID: 32352922
[TBL] [Abstract][Full Text] [Related]
31. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
32. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
Wen P; Chen SD; Wang JR; Zeng YH
Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
[TBL] [Abstract][Full Text] [Related]
33. Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
Bi Y; Jiao D; Ren J; Han X
Can J Gastroenterol Hepatol; 2022; 2022():2602121. PubMed ID: 36051250
[TBL] [Abstract][Full Text] [Related]
34. An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres
Zhang X; Lin X; Qiu H; Peng Z
J Clin Lab Anal; 2019 Oct; 33(8):e22975. PubMed ID: 31328832
[TBL] [Abstract][Full Text] [Related]
35. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
[TBL] [Abstract][Full Text] [Related]
36. Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 μm Drug-Eluting Bead Transcatheter Arterial Chemoembolization.
Wholey M; Palacios Iii R; Wholey D; Mendez A
Cureus; 2022 Apr; 14(4):e24047. PubMed ID: 35573558
[TBL] [Abstract][Full Text] [Related]
37. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients.
Song MJ; Park CH; Kim JD; Kim HY; Bae SH; Choi JY; Yoon SK; Chun HJ; Choi BG; Lee HG
Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):521-7. PubMed ID: 21537127
[TBL] [Abstract][Full Text] [Related]
38. A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials.
Wang H; Cao C; Wei X; Shen K; Shu Y; Wan X; Sun J; Ren X; Dong Y; Liu Y; Zhai B
J Cancer Res Ther; 2020; 16(2):243-249. PubMed ID: 32474508
[TBL] [Abstract][Full Text] [Related]
39. Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma.
Urbano J; Echevarria-Uraga JJ; Ciampi-Dopazo JJ; Sánchez-Corral JA; Cobos Alonso J; Anton-Ladislao A; Peña-Baranda B; Nacarino-Mejias V; González-Costero R; Muñoz Ruiz-Canela JJ; Pérez-Cuesta J; Lanciego C; de Gregorio MA
Eur J Radiol; 2020 May; 126():108966. PubMed ID: 32278280
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
